Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Transarterial Chemoembolization Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma : a Randomised , Open Label, Multicenter Controlled Trial

NCT06485466 is registered in ClinicalTrials.gov with Guohui Xu as lead sponsor.

NCT NCT06485466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06485466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Transarterial Chemoembolization Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma : a Randomised , Open Label, Multicenter Controlled Trial
Lead sponsor
Guohui Xu
Phase
Phase 3
Overall status
Recruiting
Start date
August 10, 2024
Completion date
June 30, 2028
Enrollment
101 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

apatinib, camrelizumab, transarterial chemoembolization, unresectable hepatocellular carcinoma